Mirum Pharmaceuticals MIRM 深 沪
等待开盘 05-20 09:30:00 美东时间
97.255
+1.765
+1.85%
华盛通- 最 高98.16
- 今 开95.07
- 成交量 75.15万股
- 最 低 93.87
- 昨 收 95.49
- 总市值 59.31亿
- 52周最高 114.99
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 43.50
- 委 比 -72.76%
- 总股本 6098.12万
- 历史最高 114.99
- 量 比 0.56
- 振 幅 4.49%
- 历史最低 6.513
- 每 手 1
- 风险率 18.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on OKLO, XE, MIRM, TILE, and TYRA.
05-19 21:25
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes
Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On May 15, 202...
05-19 04:44
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisco, DTE Energy and Marvell Technology on Thursday. HIGHLIGHTS * Cheesecake Factory Inc CAKE.O : JP M
05-14 15:24
Mirum Pharmaceuticals prices $600M senior notes
Mirum Pharmaceuticals (MIRM) priced a private offering of $600M aggregate principal amount of 0.00% convertible senior notes due 2032. The initial purchasers have a 13-day option to buy up to an addit...
05-13 13:58
Mirum Pharmaceuticals Announces Proposed $600M Offering Of Notes Due 2032
Miram Pharmaceuticals to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in a private placement (the "offering") to
05-13 04:19
Mirum Pharmaceuticals (MIRM) Gets a Buy from H.C. Wainwright
In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigne...
05-12 18:43
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $129
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $112 to $129.
05-07 19:44
Mirum Pharmaceuticals Signals Growth Amid Heavy Investment
Mirum Pharmaceuticals (($MIRM)) has held its Q1 earnings call. Read on for the ...
05-07 09:12
财报速睇 | Mirum Pharmaceuticals 2026财年Q1营收1.60亿美元，同比增长43.3%；归母净利润亏损7.90亿美元，同比亏损扩大5283.7%
华盛资讯5月7日讯，Mirum Pharmaceuticals公布2026财年Q1业绩，公司Q1营收1.60亿美元，同比增长43.3%，归母净利润亏损7.90亿美元，同比亏损扩大5283.7%。
05-07 05:04
